The Zhitong Finance App learned that Kai Ming Medical-B (02500) rose more than 7% in early trading. At the time of publication, it rose 7.48% to HK$6.47, with a turnover of HK$8.59 million.

According to a research report previously released by Huaan Securities, the company's operating income is expected to reach 646 million yuan, 908 million yuan, and 1,411 million yuan respectively from 2025, up 58.8%, 40.7%, and 55.3% over the previous year. According to the Comparable Companies Valuation Law, as of April 13, 2023, the average PS of H Shares Comparable Company in 2022-2024 is 19/12/8 times, and the company's PS for 2022-2024 is predicted to be 11.49/7.23/5.14 times. Considering that the company is a leading domestic innovative medical device for cardiac intervention, the “self-developed+BD” two-wheel drive has an international vision and a full four-valve layout, giving it the first “buy” rating.

The bank believes that the Structural Cardiology Circuit is the golden track for the next ten years. “Aging trend+minimally invasive treatment concept” has spawned heart valve intervention into a palm jewel in the field of structural heart disease. Transcatheter valve replacement has transformed surgical thoracotomy into interventional vascular surgery, disrupting the traditional treatment pattern and including a large number of patients who were previously at high risk and unable to be treated by surgery into the potential treatment population. According to Frost & Sullivan's forecast, the valve intervention market will have a CAGR of about 45% in 2023-2030, and the market size in 2030 will be about 42 billion yuan.